[size=6]A term infant is born with a congenital chylothorax. The neonatal team places a chest tube and begins an octreotide infusion. The parents inquire about the safety of this medication. The most common clinical adverse event in infants receiving an octreotide infusion is:

 

a Intraventricular hemorrhage

 

b Necrotizing enterocolitis

 

c Seizures

 

d Hypotension requiring vasopressors

 

e Symptomatic hypoglycemia[/size]

[size=6]A term infant is born with a congenital chylothorax. The neonatal team places a chest tube and begins an octreotide infusion. The parents inquire about the safety of this medication. The most common clinical adverse event in infants receiving an octreotide infusion is:

 

a Intraventricular hemorrhage

 

b Necrotizing enterocolitis

 

c Seizures

 

d Hypotension requiring vasopressors

 

e Symptomatic hypoglycemia[/size]

E

E

[size=6]A term infant is born with a congenital chylothorax. The neonatal team places a chest tube and begins an octreotide infusion. The parents inquire about the safety of this medication. The most common clinical adverse event in infants receiving an octreotide infusion is:

 

a Intraventricular hemorrhage

 

b Necrotizing enterocolitis

 

c Seizures

 

d Hypotension requiring vasopressors

 

e Symptomatic hypoglycemia[/size]

B

E

D

[size=6]A term infant is born with a congenital chylothorax. The neonatal team places a chest tube and begins an octreotide infusion. The parents inquire about the safety of this medication. The most common clinical adverse event in infants receiving an octreotide infusion is:

 

a Intraventricular hemorrhage

 

b Necrotizing enterocolitis

 

c Seizures

 

d Hypotension requiring vasopressors

 

e Symptomatic hypoglycemia[/size]

d

correct answer

d Hypotension requiring vasopressors

 

Octreotide has been used in a number of clinical conditions in infants. Most commonly chylothorax, hypoglycemia and gastrointestinal hemorrhage. A 2015 study of 428 infants over 15 years at 333 neonatal ICUs demonstrated that laboratory abnormalities were relatively common, particularly thrombocytopenia (47/1000 infant days), hyperkalemia (21/1000) and leukocytosis (20/1000). Hyper and hypoglycemia were rare. The most common clinical adverse event was hypotension requiring pressor support (12%). NEC complicated 2% of cases and death occurred in 3 %.